Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells Anti-Ipilimumab Antibody (4H6E1D4) [biotin], mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ipilimumab.
Clonality:
Monoclonal
Clone Designation:
[4H6E1D4]
Purity:
Protein A chromatography
Form:
Purified
Application Dilute:
ELISA detection: 0.01-0.1 µg/ml
* VAT and and shipping costs not included. Errors and price changes excepted
